Prostate Cancer - Results from #240

Novartis Pluvicto™ (177Lu-PSMA-617) Approved by FDA as First Targeted Radioligand Therapy for Treatment of PSMA Positive mCRPC March 23, 2022

Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men. March 23, 2022

Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion. March 23, 2022

Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate Cancer. March 23, 2022

Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to previous PI-RADS versions. March 23, 2022

Demographic and Psychosocial Characteristics Associated With Use of a Prostate Cancer Survivorship Website: Implications From a Multisite Randomized Controlled Trial. March 23, 2022

Exosomal LINC01213 Plays a Role in the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manners. March 23, 2022

PSMA-Targeting TGFβ-Insensitive Armored CAR T Cells in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Trial March 22, 2022

Acceptance and efficacy of recommended adjuvant radiotherapy in patients with positive lymph nodes at radical prostatectomy: a preference-based study. March 22, 2022

Success of targeted transperineal biopsy in patients on surveillance for grade group 1 prostate cancer. March 22, 2022

Nomograms for Metastasis-Free and Overall Survival for Pathologically Node Positive Prostate Cancer Patients Treated With or Without Radiation Therapy Plus Short-Term ADT. March 22, 2022

Adjusting for verification bias in diagnostic accuracy measures when comparing multiple screening tests - an application to the IP1-PROSTAGRAM study. March 22, 2022

Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progr March 22, 2022

Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography. March 21, 2022

The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. March 21, 2022

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. March 21, 2022

Attenuating adaptive VEGF-A and IL-8 signaling restores durable tumor control in AR-antagonist-treated prostate cancers. March 21, 2022

An exploration of wellbeing in men diagnosed with prostate cancer undergoing active surveillance: a qualitative study. March 21, 2022

Utility of Clinical-Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions. March 18, 2022

ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD®) in Asian men with prostate cancer. March 18, 2022

Page 13 of 1224

email news signup